Cargando…
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males
Ubrogepant is a novel, oral calcitonin gene‐related peptide (CGRP) receptor antagonist intended for the acute treatment of migraine attacks. Ubrogepant has a chemical structure distinct from previous small‐molecule CGRP receptor antagonists that were associated with elevated serum alanine aminotrans...
Autores principales: | Ankrom, Wendy, Bondiskey, Phung, Li, Chi‐Chung, Palcza, John, Liu, Wen, Dockendorf, Marissa F., Matthews, Catherine, Panebianco, Deborah, Reynders, Tom, Wagner, John A., Jakate, Abhijeet, Mesens, Sofie, Kraft, Walter K., Marcantonio, Eugene E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214647/ https://www.ncbi.nlm.nih.gov/pubmed/31899602 http://dx.doi.org/10.1111/cts.12728 |
Ejemplares similares
-
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
por: Min, K. Chris, et al.
Publicado: (2020) -
Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
por: Jakate, Abhijeet, et al.
Publicado: (2020) -
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
por: Goadsby, Peter J, et al.
Publicado: (2020) -
Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial
por: Jakate, Abhijeet, et al.
Publicado: (2019) -
Safety and tolerability of ubrogepant following intermittent,
high-frequency dosing: Randomized, placebo-controlled trial in healthy
adults
por: Goadsby, Peter J, et al.
Publicado: (2019)